European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-18

Genes And Proteins for AutoImmunity Diagnostics

Cel

"Rheumatoid arthritis (RA) and sistemic lupus erythematosus (SLE) are two autoimmune diseases that respectively affect an estimated population of 1.537.000 and 1.272.000 of patients in Europe. Such diseases show a long prodrome during which there are no clinical symptoms. In some cases, therapeutic treatments have been developed to improve patients quality of life. Therefore, reliable diagnostic/prognostic tools are necessary not only for an early diagnosis and for monitoring disease activity, but also for setting up personalized therapeutic treatments.
The clinical diagnosis of RA and SLE is assisted by the use of in vitro diagnostic tests aimed at the evaluation of the presence/level of few autoantibodies circulating in serum. Yet, this diagnostic approach is unsatisfactory because it can assist the diagnosis only after the first disease onset, it is not useful to evaluate the disease susceptibility for an early prevention, and it does not provide information to follow the disease progression for the set up of personalized therapeutic treatments.
To solve these drawbacks, the GAPAID project is aimed at supplying the SME participants of the scientific and technological activities necessary to develop a novel diagnostic / prognostic platform for patients affected by RA and SLE. To this aim the scientific activities will be focused on the discovery of the diagnostic and prognostic value of the genetic and serological profiles associated to RA and SLE. The technological activities will contribute to develop multiplex arrays for the contemporary detection of more analytes and to set up a software for the RA and SLE diagnosis / prognosis by matching the clinical, genetic, and serological data. The exploitation of the scientific and technological results will allow the SME participants to the GAPAID proposal to develop and to further commercialize both for RA and SLE an in vitro diagnostic product composed by a genetic array, a serological array, and a software."

Zaproszenie do składania wniosków

FP7-SME-2012
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

BSG-SME - Research for SMEs

Koordynator

TOSCANA BIOMARKERS S.R.L
Wkład UE
€ 181 015,82
Adres
VIA FIORENTINA 1
53100 SIENA
Włochy

Zobacz na mapie

Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Maria Claudia Alcaro (Dr.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (9)